Takeda Pharmaceutical Statistics
Total Valuation
TAK has a market cap or net worth of $41.62 billion. The enterprise value is $72.01 billion.
Important Dates
The next confirmed earnings date is Thursday, January 30, 2025, before market open.
| Earnings Date | Jan 30, 2025 |
| Ex-Dividend Date | Sep 30, 2024 |
Share Statistics
TAK has 1.59 billion shares outstanding. The number of shares has increased by 1.07% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.59B |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.57B |
Valuation Ratios
The trailing PE ratio is 20.56.
| PE Ratio | 20.56 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 0.01 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 9.61 |
| P/OCF Ratio | 6.80 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.77, with an EV/FCF ratio of 16.62.
| EV / Earnings | 35.57 |
| EV / Sales | 2.27 |
| EV / EBITDA | 7.77 |
| EV / EBIT | 15.78 |
| EV / FCF | 16.62 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.81.
| Current Ratio | 1.28 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | 4.07 |
| Debt / FCF | 9.04 |
| Interest Coverage | 5.49 |
Financial Efficiency
Return on equity (ROE) is 4.15% and return on invested capital (ROIC) is 3.29%.
| Return on Equity (ROE) | 4.15% |
| Return on Assets (ROA) | 2.77% |
| Return on Capital (ROIC) | 3.29% |
| Revenue Per Employee | $643,904 |
| Profits Per Employee | $41,075 |
| Employee Count | 49,281 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.31 |
Taxes
| Income Tax | -142.77M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.93% in the last 52 weeks. The beta is 0.46, so TAK's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -4.93% |
| 50-Day Moving Average | 13.71 |
| 200-Day Moving Average | 13.79 |
| Relative Strength Index (RSI) | 36.64 |
| Average Volume (20 Days) | 1,570,409 |
Short Selling Information
| Short Interest | 4.92M |
| Short Previous Month | 6.03M |
| Short % of Shares Out | 0.31% |
| Short % of Float | 0.31% |
| Short Ratio (days to cover) | 2.88 |
Income Statement
In the last 12 months, TAK had revenue of $31.73 billion and earned $2.02 billion in profits. Earnings per share was $1.27.
| Revenue | 31.73B |
| Gross Profit | 20.93B |
| Operating Income | 4.56B |
| Pretax Income | 366.81M |
| Net Income | 2.02B |
| EBITDA | 9.27B |
| EBIT | 4.56B |
| Earnings Per Share (EPS) | $1.27 |
Full Income StatementBalance Sheet
The company has $6.00 billion in cash and $39.15 billion in debt, giving a net cash position of -$33.16 billion or -$20.92 per share.
| Cash & Cash Equivalents | 6.00B |
| Total Debt | 39.15B |
| Net Cash | -33.16B |
| Net Cash Per Share | -$20.92 |
| Equity (Book Value) | 48.31B |
| Book Value Per Share | 30.47 |
| Working Capital | 4.65B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $6.12 billion and capital expenditures -$1.39 billion, giving a free cash flow of $4.33 billion.
| Operating Cash Flow | 6.12B |
| Capital Expenditures | -1.39B |
| Free Cash Flow | 4.33B |
| FCF Per Share | $2.73 |
Full Cash Flow StatementMargins
Gross margin is 65.95%, with operating and profit margins of 14.38% and 6.38%.
| Gross Margin | 65.95% |
| Operating Margin | 14.38% |
| Pretax Margin | 5.93% |
| Profit Margin | 6.38% |
| EBITDA Margin | 29.22% |
| EBIT Margin | 14.38% |
| FCF Margin | 13.65% |